| # | Title | Journal | Year | Citations |
|---|
| 1 | ABC multidrug transporters: structure, function and role in chemoresistance | Pharmacogenomics | 2008 | 854 |
| 2 | CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants | Pharmacogenomics | 2002 | 696 |
| 3 | Solexa Ltd | Pharmacogenomics | 2004 | 618 |
| 4 | High-resolution DNA melting analysis for simple and efficient molecular diagnostics | Pharmacogenomics | 2007 | 571 |
| 5 | Analysis of the adult human plasma metabolome | Pharmacogenomics | 2008 | 430 |
| 6 | Carbamazepine, HLA-B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations | Pharmacogenomics | 2008 | 421 |
| 7 | HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis | Pharmacogenomics | 2008 | 368 |
| 8 | Metabolic fingerprinting as a diagnostic tool | Pharmacogenomics | 2007 | 361 |
| 9 | Rationale and design of the LURIC study - a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease | Pharmacogenomics | 2001 | 321 |
| 10 | HLA-B locus in Caucasian patients with carbamazepine hypersensitivity | Pharmacogenomics | 2006 | 310 |
| 11 | Recent progress in multiple sequence alignment: a survey | Pharmacogenomics | 2002 | 289 |
| 12 | The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements | Pharmacogenomics | 2005 | 277 |
| 13 | Common risk allele in aromatic antiepileptic-drug induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese | Pharmacogenomics | 2010 | 277 |
| 14 | The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics | Pharmacogenomics | 2002 | 275 |
| 15 | Genetic variability in CYP3A5 and its possible consequences | Pharmacogenomics | 2004 | 261 |
| 16 | 57 varieties: the human cytochromes P450 | Pharmacogenomics | 2004 | 253 |
| 17 | Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations | Pharmacogenomics | 2004 | 253 |
| 18 | Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance | Pharmacogenomics | 2007 | 252 |
| 19 | MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine | Pharmacogenomics | 2009 | 244 |
| 20 | Role of OATP transporters in the disposition of drugs | Pharmacogenomics | 2007 | 241 |
| 21 | Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population | Pharmacogenomics | 2004 | 228 |
| 22 | Meta-analysis in genome-wide association studies | Pharmacogenomics | 2009 | 227 |
| 23 | Toward the $1000 human genome | Pharmacogenomics | 2005 | 222 |
| 24 | Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms | Pharmacogenomics | 2008 | 217 |
| 25 | Silent SNPs: impact on gene function and phenotype | Pharmacogenomics | 2007 | 215 |
| 26 | CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation | Pharmacogenomics | 2008 | 209 |
| 27 | Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs | Pharmacogenomics | 2003 | 208 |
| 28 | UK Biobank: from concept to reality | Pharmacogenomics | 2005 | 196 |
| 29 | Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro | Pharmacogenomics | 2007 | 196 |
| 30 | ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2 | Pharmacogenomics | 2001 | 186 |
| 31 | PTEN and PI3K/AKT in non-small-cell lung cancer | Pharmacogenomics | 2015 | 180 |
| 32 | Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity | Pharmacogenomics | 2011 | 178 |
| 33 | CYP3A4*22: promising newly identifiedCYP3A4variant allele for personalizing pharmacotherapy | Pharmacogenomics | 2013 | 178 |
| 34 | Microarray platforms – comparisons and contrasts | Pharmacogenomics | 2004 | 175 |
| 35 | Analyzing microarray data using cluster analysis | Pharmacogenomics | 2003 | 172 |
| 36 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin | Pharmacogenomics | 2009 | 171 |
| 37 | Can pharmacogenetics help rescue drugs withdrawn from the market? | Pharmacogenomics | 2006 | 168 |
| 38 | Global analysis of genetic variation in SLCO1B1 | Pharmacogenomics | 2008 | 168 |
| 39 | Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? | Pharmacogenomics | 2006 | 167 |
| 40 | Triple-negative breast cancer and the potential for targeted therapy | Pharmacogenomics | 2017 | 165 |
| 41 | HLA and pharmacogenetics of drug hypersensitivity | Pharmacogenomics | 2012 | 161 |
| 42 | Genetic network modeling | Pharmacogenomics | 2002 | 158 |
| 43 | Recent trends in protein biochip technology | Pharmacogenomics | 2000 | 157 |
| 44 | Transcriptional profiling of peripheral blood cells in clinical pharmacogenomic studies | Pharmacogenomics | 2006 | 157 |
| 45 | ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients | Pharmacogenomics | 2006 | 157 |
| 46 | Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations | Pharmacogenomics | 2008 | 156 |
| 47 | Epigenomics and breast cancer | Pharmacogenomics | 2008 | 153 |
| 48 | Transporter-mediated drug–drug interactions | Pharmacogenomics | 2011 | 148 |
| 49 | Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups | Pharmacogenomics | 2010 | 146 |
| 50 | Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans | Pharmacogenomics | 2008 | 142 |
